Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Sutro Biopharma, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 114
- −3 vs. Q4 2021
- Shares held
- 41.6M
- +1.78M (+4.5%) vs. Q4 2021
- Total value
- $342.2M
- −$251.0M (−42.3%) vs. Q4 2021
- New holders
- 24
- 40 more added
- Sold out
- 27
- 35 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 100 | $545.7M |
| Q1 2026 | 78 | $358.3M |
| Q4 2025 | 63 | $64.8M |
| Q3 2025 | 88 | $46.4M |
| Q2 2025 | 101 | $39.6M |
| Q1 2025 | 113 | $40.0M |
| Q4 2024 | 123 | $117.6M |
| Q3 2024 | 130 | $216.4M |
| Q2 2024 | 119 | $185.1M |
| Q1 2024 | 117 | $301.7M |
| Q4 2023 | 114 | $238.7M |
| Q3 2023 | 109 | $194.3M |
| Q2 2023 | 120 | $251.6M |
| Q1 2023 | 116 | $247.5M |
| Q4 2022 | 119 | $403.7M |
| Q3 2022 | 113 | $279.6M |
| Q2 2022 | 115 | $240.9M |
| Q1 2022 | 114 | $342.2M |
| Q4 2021 | 117 | $593.2M |
| Q3 2021 | 120 | $752.5M |
| Q2 2021 | 124 | $766.7M |
| Q1 2021 | 138 | $1.01B |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Sutro Biopharma, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 3,133 | $26.0K | 0.00% | −5,787−64.9% | Reduced |
| Metropolitan Life Insurance Co | 2,947 | $24.2K | 0.00% | −6,886−70.0% | Reduced |
| FourThought Financial, LLC | 1,759 | $14.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,233 | $10.0K | 0.00% | −4,210−77.3% | Reduced |
| High Net Worth Advisory Group LLC | 1,000 | $8.00K | 0.00% | +1,000 | New |
| US Bancorp | 739 | $6.00K | 0.00% | +532+257.0% | Added |
| Cutler Group LP | 560 | $4.00K | 0.00% | −2,000−78.1% | Reduced |
| Parallel Advisors, LLC | 465 | $4.00K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 519 | $4.00K | 0.00% | +481+1,265.8% | Added |
| Captrust Financial Advisors | 399 | $3.00K | 0.00% | +341+587.9% | Added |
| Simplex Trading, LLC | 403 | $3.00K | 0.00% | +403 | New |
| Washington Trust Advisors, Inc. | 179 | $1.00K | 0.00% | 00.0% | Unchanged |
| Daiwa Securities Group Inc. | 158 | $1.00K | 0.00% | 00.0% | Unchanged |
| Signaturefd, LLC | 51 | $0 | 0.00% | +51 | New |
| SV Health Investors, LLC | 0 | $0 | 0.00% | −1,824,542−100.0% | Sold out |
| Frazier Management LLC | 0 | $0 | 0.00% | −1,776,479−100.0% | Sold out |
| Loomis Sayles & Co L P | 0 | $0 | 0.00% | −1,115,835−100.0% | Sold out |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −281,702−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −220,045−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −184,765−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −160,000−100.0% | Sold out |
| Neuberger Berman Group LLC | 0 | $0 | 0.00% | −146,745−100.0% | Sold out |
| International Biotechnology Trust PLC | 0 | $0 | 0.00% | −139,331−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −101,500−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −48,700−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −48,013−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −39,377−100.0% | Sold out |
| Connective Portfolio Management, LLC | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −30,617−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −30,664−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −21,894−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −17,988−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −14,041−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −12,446−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −10,092−100.0% | Sold out |
| First Quadrant L P | 0 | $0 | 0.00% | −6,100−100.0% | Sold out |
| Jefferies Group LLC | 0 | $0 | 0.00% | −3,400−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −914−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Bellevue Asset Management, LLC | 0 | $0 | 0.00% | −83−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |